•Dompé begins enrollment for phase 3 trial on NAION intranasal therapy•Parkinson's leads to reduced contrast sensitivity•Lexitas, Ocusun dose first patient in pilot study for age-related cataract eye drop•Bausch + Lomb launches EyeGility Inserter preloaded IOL delivery system•Real-world pegcetacoplan data shows VA benefits through 18 months •Dompé begins enrollment for phase 3 trial on NAION intranasal therapy•Parkinson's leads to reduced contrast sensitivity•Lexitas, Ocusun dose first patient in pilot study for age-related cataract eye drop•Bausch + Lomb launches EyeGility Inserter preloaded IOL delivery system•Real-world pegcetacoplan data shows VA benefits through 18 months
HEADLINES
FEATURED
Pending FDA review, Nicox’s NO-donating bimatoprost formulation could receive approval and commercially launch by the end of 2027.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
